Shifting to a non-vitamin K antagonist oral anticoagulation agent from vitamin K antagonist in atrial fibrillation
ConclusionIn a contemporary setting among VKA-experienced NVAF patients; VKA is still prevalent although about 30% by December 2015 had shifted to a NOAC.
Source: Europace - Category: Cardiology Source Type: research
More News: Alcoholism | Atrial Fibrillation | Bleeding | Cardiology | Denmark Health | Diabetes | Endocrinology | Heart | Heart Disease | Heart Failure | Hypertension | Ischemic Stroke | Pradaxa | Stroke | Substance Abuse | Vitamin K | Vitamins